PG (6550) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 北極星藥業-KY

PG (6550) reported revenue of NT$1.9 million for Oct 2026, +894.8% year on year and -69.9% from the previous month. Revenue for Jan–Oct 2026 was NT$53.2 million (+52.9% year on year).

In Oct 2026, it ranked No. 145 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$16 millionNov 2024 NT$14.9 million24/11Dec 2024 NT$5.2 millionJan 2025 NT$1.3 millionFeb 2025 NT$4 million25/02Mar 2025 NT$3.9 millionApr 2025 NT$3.9 millionJun 2025 NT$4.7 million25/06Jul 2025 NT$3.2 millionAug 2025 NT$1.5 millionSep 2025 NT$13.2 million25/09Oct 2025 NT$191,000Nov 2025 NT$2.8 millionDec 2025 NT$3.1 million25/12Jan 2026 NT$18.4 millionFeb 2026 NT$16.9 millionMar 2026 NT$1.6 million26/03Apr 2026 NT$1.7 millionMay 2026 NT$1.6 millionJun 2026 NT$3.8 million26/06Aug 2026 NT$4.5 millionSep 2026 NT$6.3 millionOct 2026 NT$1.9 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$1.9 million+894.8%-69.9%
Sep 2026NT$6.3 million-52.2%+40.2%
Aug 2026NT$4.5 million+202.6%—
Jul 2026-NT$3.6 million-211.7%-193.8%
Jun 2026NT$3.8 million-19.0%+137.8%
May 2026NT$1.6 million—-4.0%
Apr 2026NT$1.7 million-57.1%+5.7%
Mar 2026NT$1.6 million-59.7%-90.7%
Feb 2026NT$16.9 million+322.9%-8.1%
Jan 2026NT$18.4 million+1,275.3%+493.0%
Dec 2025NT$3.1 million-40.7%+11.5%
Nov 2025NT$2.8 million-81.3%+1,359.7%
Oct 2025NT$191,000-98.8%-98.6%
Sep 2025NT$13.2 million+310.1%+787.1%
Aug 2025NT$1.5 million-60.6%-53.5%
Jul 2025NT$3.2 million-21.6%-31.9%
Jun 2025NT$4.7 million-5.8%—
May 2025-NT$1.1 million-115.5%-127.7%
Apr 2025NT$3.9 million-80.6%-0.8%
Mar 2025NT$3.9 million-19.3%-2.2%
Feb 2025NT$4 million-71.3%+199.0%
Jan 2025NT$1.3 million-85.1%-74.4%
Dec 2024NT$5.2 million+23.9%-64.9%
Nov 2024NT$14.9 million—-6.7%
Oct 2024NT$16 million+2,490.9%+398.2%

Jan–Oct 2026 cumulative: NT$53.2 million (+52.9% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: PG vs PEC / PG vs Lotus Pharm / PG vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

子公司CDMO及自有產品收入下降導致兩期差異

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16